Co-Diagnostics, Inc.

CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026 Study Demonstrated 97.3% Sensitivity and 96.0% Specificity Consistent Performance Across Three Test Batches Integrated Mobile and Cloud Infrastructure Already Deployed in India to Support AnticipatedCommercial Launch SALT LAKE CITY, Oct. 27, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, has completed its clinical performance study of the CoSara PCR Mycobacterium tuberculosis ("MTB" or "TB") test on the CoSara PCR Pro® instrument* and has submitted the test to India's Central Drugs Standard Control Organization ("CDSCO") for regulatory clearance.

Participation in NUWATIN 2026 to Support Advancement of Strategic Manufacturing, Technology Transfer, and Industrial Localization Initiatives Under Saudi Vision 2030 Invitation Follows Execution of Manufacturing Facility Lease in Sudair Industrial City SALT LAKE CITY, Oct. 20, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoMira Diagnostics ("CoMira"), the Company's joint venture with Arabian Eagle Manufacturing in the Kingdom of Saudi Arabia ("KSA"), has been invited by the Kingdom's Ministry of Industry and Mineral Resources to participate in the second edition of the NUWATIN 2026 Forum, scheduled for November 2026. The forum will be held under the patronage and in the presence of His Royal Highness Prince Abdulaziz bin Salman Al Saud, Minister of Industry and Mineral Resources.

Existing Sputum Sample-Preparation Technology Provides Potential Foundation for Plague Diagnostics Draws on Rapid-Response Experience with COVID-19, Mpox and Ebola Supported by Expanded Manufacturing Infrastructure SALT LAKE CITY, Oct. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted capabilities of its Co-Dx PCR Pro®* point-of-care platform that could be applied to plague diagnostics, should a public health need arise. The Company is monitoring developments following the October 2 death of a laboratory worker at a plague research institute in Irkutsk, Russia.

Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in house SALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart® mosquito surveillance laboratory installation. The order represents the Company's first complete Vector Smart laboratory installation for a Native American tribe and will enable the Tribe to perform PCR testing of mosquito pools in house.